New ccr2 receptor antagonists and uses thereof

A method for treating a neurologic disease selected from inflammatory and neuropathic pain, comprising administering an effective amount of a compound of Formula I to a patient in need thereof to treat the neurologic disease, wherein Formula I is represented by:

• or an acid addition salt thereof with a pharmacologically acceptable acid;
• wherein:
• R1 is a group selected from among —H, -halogen, —CN, —O—C1-C4 alkyl, —C1-C4 alkyl, —CH═CH2, —C≡CH, —CF3, —OCF3, —OCF2H, and —OCFH2;
• R7 is a ring selected from among —C3-C8-cycloalkyl, —C5-C10-aryl, and —C5-C10-heteroaryl, wherein the ring R7 is optionally substituted with one or more groups selected from among —CF3, —O—CF3, —S—CF3, —CN, —C1-C6-alkyl, —C(CH3)2—CN, and -halogen, or wherein the ring R7 is optionally substituted with one or more groups selected from among —O—C1-C6-alkyl and —C3-C8-cycloalkyl;
• R2 is selected from among —H, -halogen, —CN, —O—C2-C4-alkyl, —C1-C4-alkyl, —CH═CH2, —C≡CH, —CF3, —OCF3, —OCF2H, and —OCFH2;
• R3 is selected from among —H, -methyl, -ethyl, -propyl, -i-propyl, -cyclopropyl, —OCH3, —CF3, and —CN;
• n is 1, 2, or 3;
• G and E are N;
• Z is C;
• R4 denotes —H, and R5 is -L1-R18, wherein L1 is selected from among —NH—, —N(C1-C4-alkyl)-, and a bond, and R18 is —C3-C8-cycloalkyl or —C3-C8-heterocyclyl, wherein R18 is optionally substituted by one or more groups selected from among halogen, —CF3, —OCF3, —CN, —OH, —O—C1-C4-alkyl, —C1-C6-alkyl, —NH—C(O)—C1-C6-alkyl, —N(C1-C4-alkyl)-C(O)—C1-C6-alkyl, and —C(O)—C1-C6-alkyl;
• and
• R6 is selected from among —H, —C1-C4-alkyl, —OH, —O—C1-C4-alkyl, -halogen, —CN, —CF3, and —OCF3.